Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
The ESMO regular abstract lift reveals first human datasets for several projects.
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
The group toplines a phase 2 win with Alphamedix.
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
